YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Anticancer Effect of Activated Natural Killer Cells on Human Non-small Cell Lung Cancer

비소세포성폐암에 대한 자연살해세포의 항암효능

  • Received : 2011.06.09
  • Accepted : 2011.06.13
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Human NK cells, identified 30 years ago based on their ability to spontaneously kill tumor cells, constitute a subset of lymphocytes, which play an important role in the first line of immune defense and the effective function of these cells are enhanced by cytokines. Lung carcinoma has been one of the most commonly diagonosed cancer as well as the leading cause of cancer death in male. Here we provide the evidence that human natural killer cells has inhibitory effects on tumor growth of human lung cancer cell NCI-H460 (non-small cell lung cancer). Enriched NK cell population was obtained by 2 weeks cultivation in interleukin-2(IL-2)-containing medium. The resulting population comprised 26% CD3$^+$ cells, 9% CD3$^+$CD4$^+$ cells, 16% CD3$^+$CD8$^+$ cells, 76% CD56$^+$ cells, 6% CD3$^+$CD56$^+$ cells and 70% CD3$^-$CD56$^+$ cells. Activated NK cells at doese of 2.5, 5, and 10 million cells per mouse inhibited 2%, 12% and 45% of NCI-H460-induced tumor growth in nude mouse xenograft assays, repectively. This result suggests that NK cell-based immunotherapy may be used as an adoptive immunotherapy for lung cancer patients.

Keywords

References

  1. Ahmedim, J., Bray, F., Melissa, M., Jacques, F., Ward, E. and Forman, D. : Global cancer statistics. CA Cancer. J. Ciln. 69 (2011).
  2. Gaijar, A. and Lichtman, S. M. : Treatment of advanced lung cancer in erderly. Hosp. Pract. 39, 107 (2011).
  3. Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U. and Kuppen, P. J. : NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends. Immunol. 24, 603 (2003). https://doi.org/10.1016/j.it.2003.09.007
  4. Gross, S. and Walden, P. : Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunol. Lett. 116, 7 (2008). https://doi.org/10.1016/j.imlet.2007.11.012
  5. Hallett, W. H. and Murphy, W. : Natural killer cells: biology and clinical use in cancer therapy. Cell. Mol. Immunol. 1, 12 (2004).
  6. Herberman, R. B. : Cancer immunotherapy with natural killer cells. Semin Oncology 3, 27 (2002).
  7. Klingemann, H. G. : Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7, 16 (2005). https://doi.org/10.1016/S1465-3249(05)70785-4
  8. Ljunggren, H. G. and Malmberg, K. J. : Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329 (2007). https://doi.org/10.1038/nri2073
  9. Sentman, C. L., Barber, M. A., Barber, A. and Zhang, T. : NK cell receptors as tools in cancer immunotherapy. Adv. Cancer. Res. 95, 249 (2006).
  10. Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L. and Vitale, M. : NK cells and cancer. J. Immunol. 178, 4011 (2007). https://doi.org/10.4049/jimmunol.178.7.4011
  11. Bremers, A. J., Kuppen, P. J. and Parmiani, G. : Tumour immunotherapy: the adjuvant treatment of the 21st century. Eur. J. Surg. Oncol. 26, 418 (2000). https://doi.org/10.1053/ejso.1999.0908
  12. Kalinski, P., Nakamura, Y., Watchmaker, P., Giermasz, A., Muthuswamy, R. and Mailliard, R. B. : Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 36, 137 (2006). https://doi.org/10.1385/IR:36:1:137
  13. Sung, H., Kim, J. Y., Park, M. G., Kim, I., Lee, D. W., Han, S., Lee, C. and Song, S. : Anticancer effect of activated natural killer cells on human colorectal tumor. Yakhak Hoeji 54, 192 (2010).
  14. Thorne, S. H., Negrin, R. S. and Contag, C. H. : Synergistic antitumor effects of immune cell-viral biotherapy. Science 311, 1780 (2006). https://doi.org/10.1126/science.1121411
  15. Whiteside, T. L. and Herberman, R. B. : The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 704 (1995). https://doi.org/10.1016/0952-7915(95)80080-8
  16. Bobek, V., Boubelik, M., Fiserova, A., L'uptovcova, M., Vannucci, L., Kacprzak, G., Kolodzej, J., Majewski, A. M. and Hoffman, R. M. : Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer. 47, 215 (2005). https://doi.org/10.1016/j.lungcan.2004.06.012
  17. Voskoglou-Nomikos, T., Pater, J. L. and Seymour, L. : Clinical predictive value of the invitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Can. Res. 9, 4227 (2003).
  18. Le Maux Chansac, B., Moretta, A., Vergnon, I., Opolon, P., Lecluse, Y., Grunenwald, D., Kubin, M., Soria, J. C., Chouaib, S. and Mami-Chouaib, F. : NK cells infiltrating a MHC class Ideficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175, 5790 (2005). https://doi.org/10.4049/jimmunol.175.9.5790
  19. Sun, Z., Chi, L., Zhang, H., Shao, Y., Lin, Y., Li, X. and Bai, C. Immune modulation and safety profile of adoptive immunotherapy using expanded autologus activeated lymphocutes against advanced cancer. Clin. Immunol. 138, 23 (2011). https://doi.org/10.1016/j.clim.2010.08.012
  20. Salaginanni, M., Lekka, E., Moustaki, A., Lliopoulou, E. G., Baxevanis, C. N., Papamichail, M. and Perez, S. A. : Nk cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 186, 3327 (2011). https://doi.org/10.4049/jimmunol.1000652
  21. Kakimi, K., Nakajima, J. and Wada, H. : Active specific immunotherapy and cell-transfer therapy for treatment of nonsmall cell lung cancer. Lung. Cancer. 65, 1 (2009). https://doi.org/10.1016/j.lungcan.2008.10.018
  22. Kim, H. M., Kang, J. S., Lim, J., Park, S. K., Lee, K., Yoon, Y. D., Lee, C. W., Lee, K. H., Han, G., Yang, K. H., Kim, Y. J., Kim, Y. and Han, S. B. : Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch. Pharm. Res. 30, 1464 (2007). https://doi.org/10.1007/BF02977372
  23. Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K. : Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 356, 1795 (2000). https://doi.org/10.1016/S0140-6736(00)03231-1
  24. Whiteside, T. L. and Herberman, R. B. : Role of human natural killer cells in health and disease. Clin. Diagn. Lab. Immunol. 1, 125 (1994).
  25. Escudier, B., Farace, F., Angevin, E., Charpentier, F., Nitenberg, G., Triebel, F. and Hercend, T. : Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur. J. Cancer. 30A, 1078 (1994).
  26. Carlens, S., Gilljam, M., Chambers, B. J., Aschan, J., Guven, H., Ljunggren, H. G., Christensson, B. and Dilber, M. S. : A new method for in vitro expansion of cytotoxic human CD3- CD56+ natural killer cells. Hum. Immunol. 62, 1092 (2001). https://doi.org/10.1016/S0198-8859(01)00313-5
  27. Klingemann, H. G. : Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7, 16 (2005). https://doi.org/10.1016/S1465-3249(05)70785-4
  28. Alici, E., Sutlu, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H. G. and Dilber, M. S. : Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 111, 3155 (2008). https://doi.org/10.1182/blood-2007-09-110312
  29. Guven, H., Gilljam, M., Chambers, B. J., Ljunggren, H. G., Christensson, B., Kimby, E. and Dilber, M. S. : Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 17, 1973 (2003). https://doi.org/10.1038/sj.leu.2403083
  30. deMagalhaes-Silverman, M., Donnenberg, A., Lembersky, B., Elder, E., Lister, J., Rybka, W., Whiteside, T. and Ball, E. : Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J. Immunother. 23, 154 (2000). https://doi.org/10.1097/00002371-200001000-00018
  31. Terunuma, H., Deng, X., Dewan, Z., Fujimoto, S. and Yamamoto, N. : Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int. Rev. Immunol. 27, 93 (2008). https://doi.org/10.1080/08830180801911743